Bambusa Raises $169 Million to Push Bispecific Antibodies Past the Single-Target Ceiling
Biologic drugs changed immunology, but many still stop at one molecular target. In diseases driven by layered inflammatory signaling, one blocked pathway often leaves others free to keep disease active. Bambusa Therapeutics is betting that bispecific antibodies can push beyond that limit by suppressing complementary inflammatory signals at the same time.
The Boston-based company priced its initial public offering at $16 a share, at the midpoint of the targeted range, and collected about $169 million in gross proceeds after upsizing the deal by more than 1.2 million shares. The shares began trading on Nasdaq under the symbol BBTX.
That capital arrives at an early but biologically ambitious stage. Bambusa has one lead clinical asset, BBT001, already in a global Phase 1 study in atopic dermatitis, and a second clinical program, BBT002, in respiratory disease trials across multiple geographies. Both candidates are built around a core idea: inflammatory disorders often do not behave like single-pathway diseases, so a drug aimed at one target may improve only part of the clinical picture.
BBT001 Couples IL-4Rα and IL-31 to Attack Inflammation and Itch
BBT001 is a long-acting bispecific antibody designed to block interleukin-4 receptor alpha and interleukin-31. Those targets are familiar in immunology for a reason. IL-4Rα sits at the center of type 2 inflammation, while IL-31 is closely tied to itch, one of the most burdensome symptoms in atopic dermatitis and related skin disorders.
Bambusa’s strategy is to compress two therapeutic goals into one molecule: reduce the inflammatory cascade and blunt chronic pruritus. The company argues that simultaneous blockade could be especially relevant in inflammatory skin disease, where rash severity and itch often travel together but do not always improve at the same pace.
Early clinical data from the Phase 1 study point in that direction. Preliminary results showed a fast onset of effect with improvement on a disease-severity rating scale, along with rapid itch relief and robust, durable suppression of biomarkers linked to type 2 inflammation. The program has also been well tolerated so far, with no cases of conjunctivitis reported to date. That safety detail matters because conjunctivitis is a known adverse effect of Dupixent, especially in atopic dermatitis, and any new IL-4Rα-directed agent will be judged against that benchmark.
A long half-life is part of the commercial and clinical logic. Bambusa believes the preclinical and clinical package could support quarterly dosing, a more convenient interval than Dupixent’s every-two-week injections. In chronic skin disease, dosing frequency is not a cosmetic issue; lower injection burden can shape persistence, adherence, and the practical ceiling of long-term control.
One sentence captures the stakes: a broader antibody may change both symptom relief and treatment durability.
Beyond atopic dermatitis, Bambusa is considering BBT001 for prurigo nodularis, alopecia areata, bullous pemphigoid, and chronic pruritus of unknown origin. Those are all conditions where immune dysregulation and itch or inflammation can overlap in different combinations, making a multi-target biologic concept especially attractive.
Respiratory Disease Bets on Dual Control of IL-4Rα and IL-5
BBT002 takes a different route. The antibody is designed to target IL-4Rα and interleukin-5, bringing together a type 2 inflammatory pathway with one of the main drivers of eosinophilic biology. IL-5 has already been clinically validated by mepolizumab, the GSK drug marketed as Nucala, which has approvals in asthma and chronic obstructive pulmonary disease.
Bambusa’s case is straightforward: a single bispecific antibody may exert broader control over the inflammatory circuitry behind respiratory disease than a drug focused on only one axis. In the company’s framing, that could translate into more complete suppression of the biology that sustains chronic airway inflammation.
BBT002 is in a global Phase 1 study in COPD and in a Phase 1/2a study in China. A Phase 2 study in China is also evaluating the antibody in chronic rhinosinusitis with nasal polyps. Those programs place the asset in disorders where type 2 inflammation can spill across organ systems, from the lower airways to the nasal passages.
A Pipeline Built From BioNTech-Sourced Antibodies
Bambusa’s two clinical-stage programs originated at Biotheus, the China-based antibody company now owned by BioNTech. Bambusa acquired the antibodies that became BBT001 and BBT002 and moved them into the clinic under its own development plan.
The company is not stopping there. It has identified two additional candidates in partnership with the BioNTech subsidiary, including BBT003, a long-acting bispecific antibody designed to target TL1A and IL-23p19. That program is expected to enter the clinic by the end of this year for inflammatory bowel disease. The therapeutic logic is familiar to immunologists: TL1A and IL-23 sit in overlapping inflammatory networks that have attracted intense competition from large drugmakers pursuing new approaches in IBD.
Bambusa is also advancing BBT004, a bispecific antibody designed to deplete pathogenic B cells and antibody-producing plasma cells. The company has framed its platform as a way to build pipeline depth from a single molecular architecture rather than relying on isolated one-off assets.
Cash Runway Extends to Late 2028 After Series of Financings
Bambusa entered the public market after a rapid financing history. The company was formed in 2024 with about $15 million in seed funding, raised roughly $90 million in Series A capital in early 2025, and then added another $33.1 million through a Series A-2 round later that year and early this year. Before the IPO, Salvia Investment held a 22% stake, while co-founder and chief executive Shanshan Xu owned 21.2%.
As of the end of June, Bambusa reported cash of $71.6 million. With the IPO proceeds, the company expects its capital to last into late 2028. About $90 million is earmarked for BBT001, including work needed to advance it to a planned Phase 2 study in atopic dermatitis. Another $40 million is budgeted for BBT002 to reach Phase 2b testing in a respiratory indication. The rest of the funding will support BBT003 and the broader pipeline.
The near-term question is no longer whether the company can finance development. It is whether dual-target immunology can deliver enough added efficacy, tolerability, and dosing convenience to justify a crowded field of biologics already anchored to single targets. Bambusa has put real money behind that hypothesis, and the earliest clinical readout is now carrying much more weight than the pitch deck.